Literature DB >> 11099718

Choice reaction time after levodopa challenge in parkinsonian patients.

T Müller1, S Benz, H Przuntek.   

Abstract

Various types of choice reaction time paradigms demonstrated deficits in the preparation and execution of movements in parkinsonian subjects. These studies showed controversial results, since they included parkinsonian individuals being: (i) previously untreated; (ii) off; or (iii) on anti-parkinsonian medication. Moreover, these trials do not take into consideration the acute effects of levodopa administration. Objective of this study was to determine the effect of long-term dopaminergic substitution therapy within a standardized levodopa challenge test in combination with a repeatedly performed choice reaction time task in parkinsonian individuals. Parkinsonian participants consisted of previously untreated, so-called "de-novo" patients and of individuals, who were chronically substituted with dopaminergic drugs, but were taken off medication for at least 12 h. All participants took 250 mg levodopa/benserazide after assessment of baseline data. Then we repeatedly measured choice reaction- and movement time within the next 90 min. No significant change of the assessed task data appeared in the "de-novo" group, but reaction- and movement time significantly shortened in previously treated subjects. Sedative effects of levodopa and/or dopaminergic overstimulation hypothetically explain the results of the previously untreated patients, whereas long-term dopaminergic substitution therapy hypothetically causes tolerance to these phenomena in treated parkinsonian individuals. Future studies on parkinsonian subjects should discuss their results on the basic pathophysiology or basal ganglia dysfunction in the light of a putative impact of long-term anti-parkinsonian drug therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099718     DOI: 10.1016/s0022-510x(00)00436-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.

Authors:  Nathalie Turle-Lorenzo; Nathalie Breysse; Christelle Baunez; Marianne Amalric
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

2.  Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease.

Authors:  Thomas Müller; Ali Harati
Journal:  J Neural Transm (Vienna)       Date:  2020-02-01       Impact factor: 3.575

3.  Dissociable effects of dopamine on learning and performance within sensorimotor striatum.

Authors:  Daniel K Leventhal; Colin Stoetzner; Rohit Abraham; Jeff Pettibone; Kayla DeMarco; Joshua D Berke
Journal:  Basal Ganglia       Date:  2014-06-01

4.  Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.

Authors:  S A Molloy; E N Rowan; J T O'Brien; I G McKeith; K Wesnes; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-04       Impact factor: 10.154

5.  Neurophysiological mechanisms of circadian cognitive control in RLS patients - an EEG source localization study.

Authors:  Rui Zhang; Moritz D Brandt; Wiebke Schrempf; Christian Beste; Ann-Kathrin Stock
Journal:  Neuroimage Clin       Date:  2017-06-15       Impact factor: 4.881

6.  Response monitoring in de novo patients with Parkinson's disease.

Authors:  Rita Willemssen; Thomas Müller; Michael Schwarz; Michael Falkenstein; Christian Beste
Journal:  PLoS One       Date:  2009-03-27       Impact factor: 3.240

7.  Quantitative electromyographic analysis of reaction time to external auditory stimuli in drug-naïve Parkinson's disease.

Authors:  Do-Young Kwon; Byung Kyu Park; Ji Won Kim; Gwang-Moon Eom; Junghwa Hong; Seong-Beom Koh; Kun-Woo Park
Journal:  Parkinsons Dis       Date:  2014-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.